You are here

Article Text

Article menu
Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Case report
Faecal microbiota transplantation for refractory Clostridiumdifficile infection
  1. Aravind Gokul Tamilarasan1,
  2. Peter Irving1,
  3. Christopher IS Meadows2,3 and
  4. Simon Goldenberg4
  1. 1Department of Gastroenterology, Guy's and St Thomas' Hospitals, London, UK
  2. 2Department of Critical Care, Guy's and St Thomas' Hospitals, London, UK
  3. 3Faculty of Life Sciences and Medicine, King's College London, London, London, UK
  4. 4Centre for Clinical Infection and Diagnostics Research, Guy's and St Thomas' NHS Foundation Trust, London, UK
  1. Correspondence to Dr Aravind Gokul Tamilarasan; gt_tamilarasan{at}hotmail.com

Abstract

Faecal microbiota transplantation (FMT) has become a part of the treatment algorithm for Clostridium difficile infection (CDI), particularly for recurrent infections when antibiotics have diminishing efficacy. Notably, despite a significant proportion of patients suffering from refractory disease, there is a general lack of evidence describing the use of FMT in this patient cohort. We present here a case of successful treatment of refractory CDI in a patient under critical care.

  • infection (gastroenterology)
  • adult intensive care
  • infectious diseases

https://doi.org/10.1136/bcr-2019-231027

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors All authors (AGT, PI, CM, SG) contributed to report writing, editing and proofing of the final manuscript. All authors were closely involved in the patient’s care.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.